Patent application number | Description | Published |
20100278866 | BORRELIA DIAGNOSTICS AND SCREENING METHODS - Compositions and methods of detecting | 11-04-2010 |
20100317026 | VMP-Like Sequences Of Pathogenic Borrelia - The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic | 12-16-2010 |
20120122238 | VMP-Like Sequences of Pathogenic Borrelia - The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borreliae, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies. | 05-17-2012 |
20130210651 | Borrelia Diagnostics and Screening Methods - The present invention provides methods of detecting | 08-15-2013 |
20130245234 | VMP-LIKE SEQUENCES OF PATHOGENIC BORRELIA - The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borreliae, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies. | 09-19-2013 |
Patent application number | Description | Published |
20100017307 | METHOD AND SYSTEM FOR ON-LINE, REAL-TIME, INTERACTIVE COLLABORATIVE VISUALIZATION - An inventive system and method for collaborative commerce is presented. The invention comprises activating an art board, placing items onto the art board, inviting users to interact with the art board, and collaborating with the invited users. Additional features and functions include purchasing items shown on the art board, including by placing the items in a shopping cart, using e-mail, text messaging, and instant messaging to invite users, who may be chosen from a buddy list. Collaborating can be performed using voice chatting, video chatting, instant messaging, and text messaging, and includes examining reviews, ratings, reputations, and recommendations, and also includes displaying details regarding the items. In addition, reports comprising information regarding the items can be generated. A toolbar can be located on the art board and used to initiate inviting of users and placing of items onto the art board. | 01-21-2010 |
Patent application number | Description | Published |
20100203631 | ANTIBODIES TO ALPHA-SYNUCLEIN - The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes. | 08-12-2010 |
20120204275 | APOE IMMUNOTHERAPY - The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases. | 08-09-2012 |
20120258041 | COMPOSITIONS AND METHODS FOR TREATING DISEASES OF PROTEIN AGGREGATION INVOLVING IC3B DEPOSITION - The invention provides antibodies that preferentially bind to iC3b relative to C3b. These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of diseases associated with deposits of the fragment. | 10-11-2012 |
20130317199 | Antibodies To Alpha-Synuclein - The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes. | 11-28-2013 |
20140050733 | APOE IMMUNOTHERAPY - The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases. | 02-20-2014 |
20140127131 | ANTIBODIES RECOGNIZING ALPHA-SYNUCLEIN - The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of α-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with α-synuclein, particularly accumulation of α-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA). | 05-08-2014 |
20140127225 | COMPOSITIONS AND METHODS FOR TREATING DISEASES OF PROTEIN AGGREGATION INVOLVING IC3B DEPOSITION - The invention provides antibodies that preferentially bind to iC3b relative to C3b. These antibodies find use in treatment and prophylaxis of a variety of diseases associated with deposits of the fragment. | 05-08-2014 |
20140186371 | COMPOSITIONS AND METHODS FOR TREATING DISEASES OF PROTEIN AGGREGATION INVOLVING IC3B DEPOSITION - The invention provides antibodies that preferentially bind to iC3b relative to C3b. These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of diseases associated with deposits of the fragment. | 07-03-2014 |
20140348843 | APOE IMMUNOTHERAPY - The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases. | 11-27-2014 |
20150110776 | ANTIBODIES THAT RECOGNIZE IAPP - The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions. | 04-23-2015 |
20150110777 | ANTIBODIES THAT RECOGNIZE IAPP - The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions. | 04-23-2015 |
20150191541 | ANTIBODIES THAT RECOGNIZE IAPP - The invention provides monoclonal antibody 8A9 and related antibodies. The 8A9 antibody binds to an epitope within residues 1-10 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions. | 07-09-2015 |
20150259404 | ANTIBODIES RECOGNIZING ALPHA-SYNUCLEIN - The invention provides monoclonal antibody 5Cl and related antibodies. The 5Cl antibody binds to an epitope within residues 118-126 of α-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with α-synuclein, particularly accumulation of α-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA). | 09-17-2015 |
Patent application number | Description | Published |
20090176256 | Methods and Products for Evaluating an Immune Response to a Therapeutic Protein - The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre. | 07-09-2009 |
20120195884 | METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN - The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre. | 08-02-2012 |
20150071917 | METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN - The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre. | 03-12-2015 |
Patent application number | Description | Published |
20130325481 | VOICE INSTRUCTIONS DURING NAVIGATION - A method of providing navigation on an electronic device when the display screen is locked. The method receives a verbal request to start navigation while the display is locked. The method identifies a route from a current location to a destination based on the received verbal request. While the display screen is locked, the method provides navigational directions on the electronic device from the current location of the electronic device to the destination. Some embodiments provide a method for processing a verbal search request. The method receives a navigation-related verbal search request and prepares a sequential list of the search results based on the received request. The method then provides audible information to present a search result from the sequential list. The method presents the search results in a batch form until the user selects a search result, the user terminates the search, or the search items are exhausted. | 12-05-2013 |
20140218392 | INTELLIGENT ADJUSTMENT OF MAP VIEWPORTS AT LAUNCH - A method of selectively displaying maps on a mobile device. The method sends a map application, which had been displaying a first map, to the background. The method then returns the map application to the foreground. The method then determines whether to redisplay the previous map or display a map surrounding the then current location of the device. The determination is based on various factors including user interaction, time that the map application has been in the background and distance traveled while the map application is in the background. | 08-07-2014 |
20150253148 | Map Application with Improved Search Tools - Some embodiments of the invention provide a mapping application with novel tools for examining potential destinations and routes to the potential destinations. In some embodiments, the mapping application includes a route preview page that provides a novel combination of user element tools that allow a user (1) to explore alternative routes to a selected destination, (2) to explore routes to other destinations in a list of destinations. In some embodiments, the route overview page also provides a modal zoom tool that allows the map on this page to zoom to the destination/search result or zoom out to an overview of the entire route to the destination/search result. These three tools (i.e., the tool for exploring alternative routes to one location, the tool for exploring routes to other locations, and the tool for providing modal zoom operations) are highly beneficial in allowing a user to navigate to a location because they allow the user to quickly explore the two-dimensional solution space of possible locations and possible routes to the locations. | 09-10-2015 |